Pharmacodynamics of combined estrogen-progestin oral contraceptives: 2. effects on hemostasis

  title={Pharmacodynamics of combined estrogen-progestin oral contraceptives: 2. effects on hemostasis},
  author={Manuela Farris and Carlo Bastianelli and Elena Rosato and Ivo Brosens and Giuseppe Benagiano},
  journal={Expert Review of Clinical Pharmacology},
  pages={1129 - 1144}
ABSTRACT Introduction: The pharmacodynamic effects of various combined oral estrogen-progestin combinations (COC) are examined for their components alone or in the various combined formulations. Special emphasis is given to products containing natural estrogens. Areas covered: Recent information on the effect of androgens, estrogens, progestins, as well as various COC combinations on the coagulation cascade will be reviewed aiming at providing an updated picture. The present article reviews… 

Metabolic and laboratory effects of a progestin-only pill containing drospirenone 4 mg in comparison to desogestrel 75 µg: a double-blind, double-dummy, prospective, randomised study

  • S. PalaciosE. ColliP. Regidor
  • Medicine, Biology
    The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
  • 2021
The results confirm the beneficial properties of the drospirenone-only pill on a variety of metabolic parameters and on coagulatory parameters, and there was no impact on hemostasis.

Estetrol: A New Choice for Contraception

E4/DRSP effectively inhibits ovulation, with a similar effect on endometrium thickness than that of EE-containing COCs, and this combination also could drive a lower risk of venous thromboembolism than EE- containing C OCs.

Estetrol: a new estrogen component in combined oral contraceptives: A review

Evidence is scarce about the effect of the new combination on the breast and bone tissue, and further studies are needed to consolidate the available data and investigate possible side effects of prolonged use of E4-containing combined oral contraceptives compared to known ethinylestradiol and estradiol-containing combinations.

Effects of low-dose combined oral contraceptives and protein S K196E mutation on anticoagulation factors: a prospective observational study

Reduced antigen and activity levels of PS and antithrombin and increased activity level of PC were observed even during the first cycle of low-dose COC use, and the effects on PS and PC activities were also observed in the hormone-free interval.

Oral Contraceptives and Venous Thromboembolism: Focus on Testing that May Enable Prediction and Assessment of the Risk.

Specific attention will be given to the endogenous thrombin potential-based activated protein C resistance, a test aiming at assessing the thrombogenicity induced by hormonal therapies and inherited or acquiredThrombophilia.

Unintended pregnancy in users of nomegestrol acetate and 17β-oestradiol (NOMAC-E2) compared with levonorgestrel-containing combined oral contraceptives: final results from the PRO-E2 study

  • S. ReedC. Koro K. Heinemann
  • Medicine
    The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
  • 2021
NOMAC-E2 demonstrated superior contraceptive effectiveness compared to COCLNG, likely due to the comparatively short hormone-free interval and possibly reinforced by the long half-life of NOMAC.

Blood Hormones and Venous Thromboembolic Events: Lack of Association or Lack of Standardization?

An analysis from the Atherosclerosis Risk in Communities (ARIC) Study was performed to investigate whether circulating blood levels of endogenous hormones, such as dehydroepiandrosterone sulphate (DHEAS), testosterone and sex hormone-binding globulin (SHBG), were associated with the incidence of VTE in men and post-menopausal women receiving HRT or no HRT.

A safety evaluation of current medications for adult women with the polycystic ovarian syndrome not pursuing pregnancy

There is no solid evidence supporting that the use of combined oral contraceptives in women with PCOS increases the risk of cardiovascular or thromboembolic events compared with the general population.

Thromboembolic complications of hormonal therapy in women. Position of cardiologist

Clinical observations are provided illustrating the administration of hormonal therapy to women is reasonable to be discussed and agreed with cardiologists and/or general practitioners, and the patients would be informed about possible cardiovascular complications of such therapy for an adequate selfcontrol.



Pharmacodynamics of combined estrogen-progestin oral contraceptives: 1. Effects on metabolism

ABSTRACT Introduction: The risk-benefit profile of any pharmacologic agent must be evaluated against risks connected with the events to be avoided. This is especially true in the case of hormonal

Differential effects of progestins on hemostasis.

Effect of oral contraceptives on haemostasis variables.

The role of PGs in the effects of COCs is significant and their design may in addition to reduction of oestrogen dosage be important in reducing haemostatic complications, according to summarised literature data.

Hemostatic Effects of a Novel Estradiol-Based Oral Contraceptive

The novel COC containing estradiol valerate/dienogest had similar or less pronounced effects on hemostatic parameters than ethinylestradiol/ levonorgestrel.

Effects of newer oral contraceptives on the inhibition of coagulation and fibrinolysis in relation to dosage and type of steroid.

Coagulation effects of oral contraception.

  • J. Bonnar
  • Medicine
    American journal of obstetrics and gynecology
  • 1987

Effects of progestogens on haemostasis.

  • H. Kuhl
  • Medicine, Biology
  • 1996

Estradiol valerate and dienogest: a new approach to oral contraception

Estradiol valerate plus dienogest (E2V/DNG) is now available in a four-phasic regimen that integrates an estrogen stepdown and progestin stepup dosing approach along with a short two-day hormone-free interval.

Comparison of the Impact of Four Generations of Progestins on Hemostatic Variables

  • Sandra OslakovićR. Zadro
  • Biology, Medicine
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • 2014
Significant difference between oral contraceptives was found in antithrombin, protein C, protein S activities, and PAI-1 values, but changes were mostly within reference range.